# Venetoclax Plus RIC Regimen Allo-HSCT for Elderly Patients With High-risk Myeloid Malignancies

> **NCT05583175** · PHASE2 · UNKNOWN · sponsor: **Xianmin Song, MD** · enrollment: 50 (estimated)

## Conditions studied

- Leukemia, Myeloid, Acute
- MDS
- Hematopoietic Stem Cell Transplantation
- Myeloid Malignancy

## Interventions

- **DRUG:** Venetoclax plus RIC

## Key facts

- **NCT ID:** NCT05583175
- **Lead sponsor:** Xianmin Song, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-11-01
- **Primary completion:** 2024-11-01
- **Final completion:** 2024-11-01
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2023-11-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05583175

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05583175, "Venetoclax Plus RIC Regimen Allo-HSCT for Elderly Patients With High-risk Myeloid Malignancies". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05583175. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*